Clinical trials: Diagnosis, Dual (Psychiatry)
Anxiety Disorder, Panic Disorder
Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients With Anxiety
OBJECTIVES: I. Determine whether the benzodiazepine alprazolam reinforces self-medication behavior in anxious patients with varying histories of using other drugs. II.
- Trial name
- NCT00004373
- Testing
- alprazolam
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Psychiatric Disorders
Influence of Oxytocin on the Startle Reflex and on Its Modulation
Oxytocin (OXT) is currently regarded as a crucial neuropeptide in the mediation of various human social behaviors, e.g. social affiliation, social recognition, and the modulation of anxiety, mood, and aggression.
- Trial name
- NCT01066299
- Testing
- Syntocinon®, inactive nasal spray
- Where
- Switzerland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Diagnosis, Dual (Psychiatry)
Animal-Assisted Therapy in the Residential Treatment of Schizophrenia and Addictions
Animal-assisted therapy (AAT) is a complementary intervention of therapy that has shown positive results in the treatment of various pathologies.
- Trial name
- NCT05103865
- Testing
- Animal-assisted therapy (AAT), usual treatment
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Miguel Monfort Montolio
Dyskinesia, Medication-induced
Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia
An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia
- Trial name
- NCT00175955
- Testing
- Levetiracetam
- Where
- 7 sites in Belgium, Bulgaria
- Volunteers
- 70 people
- Sponsor
- UCB Pharma
Vascular Dementia
Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.
Study purpose: evaluate clinical efficacy ands afety of Prospekta in the treatment of cognitive, behavioral and psychiatric disorders in patients with vascular dementia.
- Trial name
- NCT04552041
- Testing
- Prospekta
- Where
- 33 sites in Russia
- Volunteers
- 406 people
- Sponsor
- Materia Medica Holding
Huntington Disease
Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers
To assess the safety and tolerability of five doses of PBF-999 (160 mg and 320mg) after repeated (8 days) single daily oral dose administration in young male and female healthy subjects.
- Trial name
- NCT02907294
- Testing
- PBF-999 / 160 mg, PBF-999 / 320 mg
- Where
- Spain
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Palobiofarma SL
Parkinson Disease
Phase II Double Blind Controlled Trial of Nigral Grafting in Patients With Parkinson's Disease
OBJECTIVES: I. Determine the effectiveness of fetal nigral transplantation in patients with Parkinson's disease.
- Trial name
- NCT00004387
- Testing
- fetal nigral transplantation
- Volunteers
- 34 people
- Sponsor
- National Center for Research Resources (NCRR)
Mental Disorder, Intellectual Disability
Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
Quality of mental health services provision for adults with intellectual disability and comorbid mental disorder is considered inadequate and therefore in need of further improvement.
- Trial name
- MEMENTA (NCT01695395)
- Where
- 3 sites in Germany
- Volunteers
- 371 people
- Sponsor
- Technische Universität Dresden
Psychiatric Disorders
Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders
This study is designed to assess the safety, tolerability, and pharmacokinetics (PK) of multiple doses and ratios of xanomeline and trospium chloride in an IR capsule (KarXT) and dual-burst release of xanomeline with…
- Trial name
- NCT06853171
- Testing
- KarXT, KarX-EC
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Bristol-Myers Squibb
Depressive Disorder, Major
A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder
A Placebo Controlled Study Evaluating Efficacy And Safety of Medication In Patients With Major Depressive Disorder (MDD)
- Trial name
- NCT00048204
- Testing
- GW597599B, paroxetine
- Volunteers
- 372 people
- Sponsor
- GlaxoSmithKline